S100A10通过细胞外囊泡转移及调控其蛋白货物促进肝细胞癌发生发展
本研究探讨S100A10及细胞外囊泡相关S100A10(EV-S100A10)在肝细胞癌(HCC)进展中的作用与机制。体外和体内实验显示S100A10促进HCC起始、自我更新、化疗耐药和转移,且HCC细胞可将S100A10分泌至细胞外囊泡中;S100A10富集的细胞外囊泡增强HCC细胞干性和转移能力,上调EGFR、AKT和ERK信号并促进上皮-间质转化。EV-S100A10还可作为趋化因子促进HCC细胞运动,并通过与整合素αⅤ物理结合介导MMP2、纤连蛋白和EGF与囊泡膜结合。用S100A10中和抗体阻断EV-S100A10可显著消除这些增强效应。结论认为S100A10通过细胞外囊泡转移及调控囊泡蛋白货物促进HCC进展,EV-S100A10可能是HCC进展的潜在治疗靶点和生物标志物。
要点
- S100A10在体外和体内促进HCC起始、自我更新、化疗耐药和转移。
- HCC细胞可将S100A10分泌至细胞外囊泡,S100A10富集的囊泡增强HCC细胞干性和转移能力。
- S100A10中和抗体阻断EV-S100A10可显著消除上述增强效应。
核心结论
- S100A10通过其在细胞外囊泡中的转移及调控囊泡蛋白货物显著促进HCC进展。
- EV-S100A10可能是HCC进展的潜在治疗靶点和生物标志物。
研究设计与样本
- 在体外和体内研究S100A10及EV-S100A10在HCC进展中的功能与机制。
- 使用S100A10中和抗体评估EV-S100A10的意义。
主要发现
- S100A10在体外和体内促进HCC起始、自我更新、化疗耐药和转移。
- HCC细胞在体外和患者血浆中均将S100A10分泌至细胞外囊泡。
- S100A10富集的细胞外囊泡增强HCC细胞干性和转移能力,上调EGFR、AKT和ERK信号,并促进上皮-间质转化。
- EV-S100A10作为趋化因子促进HCC细胞运动。
- S100A10调控细胞外囊泡中的蛋白货物,并通过与整合素αⅤ物理结合介导MMP2、纤连蛋白和EGF与囊泡膜结合。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Growing evidence indicates that tumour cells exhibit characteristics similar to their lineage progenitor cells. We found that S100 calcium binding protein A10 (S100A10) exhibited an expression pattern similar to that of liver progenitor genes. However, the role of S100A10 in hepatocellular carcinoma (HCC) progression is unclear. Furthermore, extracellular vesicles (EVs) are critical mediators of tumourigenesis and metastasis, but the extracellular functions of S100A10, particularly those related to EVs (EV-S100A10), are unknown. DESIGN: The functions and mechanisms of S100A10 and EV-S100A10 in HCC progression were investigated in vitro and in vivo. Neutralising antibody (NA) to S100A10 was used to evaluate the significance of EV-S100A10. RESULTS: Functionally, S100A10 promoted HCC initiation, self-renewal, chemoresistance and metastasis in vitro and in vivo. Of significance, we found that S100A10 was secreted by HCC cells into EVs both in vitro and in the plasma of patients with HCC. S100A10-enriched EVs enhanced the stemness and metastatic ability of HCC cells, upregulated epidermal growth factor receptor (EGFR), AKT and ERK signalling, and promoted epithelial-mesenchymal transition. EV-S100A10 also functioned as a chemoattractant in HCC cell motility. Of significance, S100A10 governed the protein cargos in EVs and mediated the binding of MMP2, fibronectin and EGF to EV membranes through physical binding with integrin αⅤ. Importantly, blockage of EV-S100A10 with S100A10-NA significantly abrogated these enhancing effects. CONCLUSION: Altogether, our results uncovered that S100A10 promotes HCC progression significantly via its transfer in EVs and regulating the protein cargoes of EVs. EV-S100A10 may be a potential therapeutic target and biomarker for HCC progression.
引用
- Wang X, Huang H, Sze KM, et al. S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos. Gut. 2023. PMID: 36631249. doi:10.1136/gutjnl-2022-327998
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。